Home > Insider Trading > Filing (0001209191-14-043776)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1437402	Ardelyx Inc.	ARDX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1405712	Cmea Ventures Vii Lp	One Letterman Drive Building C, Suite Cm5400 San Francisco CA 94129		No	No	Yes	No
1405972	Cmea Ventures Vii (Parallel) Lp	One Letterman Drive Building C, Suite Cm500 San Francisco CA 94129		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-06-24	2,840,466	$0.00	2,840,466	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-06-24	857,595	$0.00	3,698,061	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-06-24	308,905	$14.00	4,006,966	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2014-06-24	72,830	$0.00	72,830	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-06-24	21,989	$0.00	94,819	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-06-24	7,921	$14.00	102,740	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Series B Preferred Stock	Series B Preferred Stock Purchase Warrant	Disposition	2014-06-24	131,912	$0.00	131,912	$0.09
Series B Preferred Stock	Series B Preferred Stock Purchase Warrant	Disposition	2014-06-24	43,970	$0.00	43,970	$0.09
Series B Preferred Stock	Series B Preferred Stock Purchase Warrant	Disposition	2014-06-24	3,382	$0.00	3,382	$0.09
Series B Preferred Stock	Series B Preferred Stock Purchase Warrant	Disposition	2014-06-24	1,127	$0.00	1,127	$0.09
Common Stock	Series B Preferred Stock	Acquisiton	2014-06-24	175,882	$0.00	174,750	$0.00
Common Stock	Series B Preferred Stock	Acquisiton	2014-06-24	4,479	$0.00	4,479	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-06-24	1,132	$0.00	1,132	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-06-24	30	$0.00	30	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-06-24	2,840,466	$0.00	2,840,466	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-06-24	72,830	$0.00	72,830	$0.00
Common Stock	Series A Preferred Stock	Disposition	2014-06-24	857,595	$0.00	857,595	$0.00
Common Stock	Series A Preferred Stock	Disposition	2014-06-24	21,989	$0.00	21,989	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2020-11-16	No	4	X	Indirect
0	2021-04-14	No	4	X	Indirect
0	2020-11-16	No	4	X	Indirect
0	2021-04-14	No	4	X	Indirect
2,841,598		No	4	X	Indirect
72,860		No	4	X	Indirect
2,840,466		No	4	J	Indirect
72,830		No	4	J	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

Each share of Series A Preferred and Series B Preferred Stock automatically converted into one share of Issuer's Common Stock upon the consummation of the Issuer's initial public offering (the "IPO"), and warrants to purchase Series B Preferred Stock automatically net exercised immediately prior to such conversion based on the Issuer's IPO stock price. The disposition and acquisition of warrant shares reported herein reflect the automatic withholding of shares by the company pursuant to such net exercise.
The shares are directly held by CMEA Ventures VII, LP.
The shares are directly held by CMEA Ventures (Parallel) VII, LP.
The Series B Preferred Stock Purchase Warrants cease to be exercisable following the consummation of the IPO.
The Series A Preferred and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1:1 basis upon the completion of Issuer's IPO.
The expiration date is not relevant to the conversion of these securities.
Immediately prior to the closing of the IPO, the warrants automatically net exercised by their terms into Series B Preferred Stock, which allowed the holder to pay the exercise price of the warrants by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.